Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00478218 · OUTCOME

Duration of Response (DOR)

Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma · Source last updated 2011-08-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
up to 5 years

What was measured

Duration of response was calculated from the documentation (date) of first response (CR, VGPR, or PR) until the date of progression or last follow-up in the subset of patients who responded. The median DOR with 95%CI was estimated using the Kaplan Meier method.

Analysis population: Participants who achieved a partial response(PR) or better were evaluable for this analysis.

Groups in this outcome

LCD (Cyclophosphamide 300 mg/m^2)

Lenalidomide 25 mg PI days 1-21 Cyclophosphamide 300 mg/m\^2 PO days 1, 8, 15 Dexamethasone 40 mg PI days 1, 8, 15, 22

LCD (Cyclophosphamide 300 mg)

Lenalidomide 25 mg PI days 1-21 Cyclophosphamide 300 mg PO days 1, 8, 15 Dexamethasone 40 mg PI days 1, 8, 15, 22

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
LCD (Cyclophosphamide 300 mg/m^2)26
LCD (Cyclophosphamide 300 mg)16

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
LCD (Cyclophosphamide 300 mg/m^2)26.1Not reported17.531.7Not reported
LCD (Cyclophosphamide 300 mg)NANot reportedNANAMedian DOR for group 2 has not been attained.
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        17.5
        upper Limit
        31.7
        value
        26.1
      2. comment
        Median DOR for group 2 has not been attained.
        group Id
        OG001
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      26
    2. group Id
      OG001
      value
      16
    units
    Participants
description
Duration of response was calculated from the documentation (date) of first response (CR, VGPR, or PR) until the date of progression or last follow-up in the subset of patients who responded. The median DOR with 95%CI was estimated using the Kaplan Meier method.
dispersion Type
95% Confidence Interval
groups
  1. description
    Lenalidomide 25 mg PI days 1-21 Cyclophosphamide 300 mg/m\^2 PO days 1, 8, 15 Dexamethasone 40 mg PI days 1, 8, 15, 22
    id
    OG000
    title
    LCD (Cyclophosphamide 300 mg/m^2)
  2. description
    Lenalidomide 25 mg PI days 1-21 Cyclophosphamide 300 mg PO days 1, 8, 15 Dexamethasone 40 mg PI days 1, 8, 15, 22
    id
    OG001
    title
    LCD (Cyclophosphamide 300 mg)
param Type
MEDIAN
population Description
Participants who achieved a partial response(PR) or better were evaluable for this analysis.
reporting Status
POSTED
time Frame
up to 5 years
title
Duration of Response (DOR)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice